Insilico Medicine and Tenacia expand AI-driven R&D collaboration
TheraCryf advances lead addiction programme to final preclinical stage
Collegium to acquire AZSTARYS from Corium Therapeutics
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
GenomOncology partners with WeTrials to support CNS cancer clinical trials
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial
Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Insilico Medicine signs co-development collaboration agreement with Hygtia Therapeutics
Orsini chosen as specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve)
Hemispherian secures US patent allowance expanding GLIX1 patent protection
MavriX Bio reports first patient dosed in Phase 1/2 trial of MVX-220 for AS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation